Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for uniQure N.V. (QURE : NSDQ)

• Company Description    UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. Number of Employees: 463

• Price / Volume Information    Yesterday's Closing Price: $13.82 Daily Weekly Monthly 20 Day Moving Average: 555,729 shares Shares Outstanding: 46.65 (millions) Market Capitalization: $644.67 (millions) Beta: 1.13 52 Week High: $38.80 52 Week Low: $12.52 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.21% -12.57% 12 Week -13.68% -6.34% Year To Date -33.37% -20.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL PAASHEUVELWEG 25 - AMSTERDAM,P7 1105 BP NLD ph: 31-20-240-6000 fax: 31-20-566-9272 m.cantor@uniqure.com http://www.uniqure.com

• General Corporate Information    Officers Matthew Kapusta - Chief Executive Officer and Director Christian Klemt - Chief Financial Officer Madhavan Balachandran - Director Robert Gut - Director Rachelle Jacques - Director Peer Information uniQure N.V. (CORR.) uniQure N.V. (RSPI) uniQure N.V. (CGXP) uniQure N.V. (BGEN) uniQure N.V. (GTBP) uniQure N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N90064101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 07/25/22 Share - Related Items Shares Outstanding: 46.65 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $644.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.54 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/25/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 2.01 PEG Ratio: - Price Ratios Price/Book: 1.18 Price/Cash Flow: 1.90 Price / Sales: 1.23 EPS Growth vs. Year Ago Period: -9.89% vs. Previous Quarter: -688.24% Sales Growth vs. Year Ago Period: 294.71% vs. Previous Quarter: -96.89% ROE 03/31/22 - 54.85 12/31/21 - 64.35 09/30/21 - 75.59 ROA 03/31/22 - 41.53 12/31/21 - 48.26 09/30/21 - 56.68 Current Ratio 03/31/22 - 12.94 12/31/21 - 17.09 09/30/21 - 14.16 Quick Ratio 03/31/22 - 12.94 12/31/21 - 17.09 09/30/21 - 14.17 Operating Margin 03/31/22 - 61.76 12/31/21 - 62.90 09/30/21 - 64.09 Net Margin 03/31/22 - 61.76 12/31/21 - 62.90 09/30/21 - 64.09 Pre-Tax Margin 03/31/22 - 62.22 12/31/21 - 63.51 09/30/21 - 61.52 Book Value 03/31/22 - 11.70 12/31/21 - 12.89 09/30/21 - 12.78 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.19 12/31/21 - 0.17 09/30/21 - 0.12 Debt-to-Capital 03/31/22 - 15.66 12/31/21 - 14.49 09/30/21 - 10.80

Powered by Zacks Investment Research ©